Bank of America Corp DE Lowers Stock Holdings in CVS Health Corporation $CVS

Bank of America Corp DE decreased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 0.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 9,351,969 shares of the pharmacy operator’s stock after selling 67,667 shares during the period. Bank of America Corp DE’s holdings in CVS Health were worth $671,658,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd increased its position in CVS Health by 407.2% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Swiss RE Ltd. acquired a new stake in shares of CVS Health in the fourth quarter worth $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the 4th quarter valued at $28,000. Global Trust Asset Management LLC lifted its holdings in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. acquired a new stake in CVS Health in the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Wall Street’s generally bullish recommendations continue to support the investment case, suggesting analysts see further upside in CVS Health’s healthcare-services and pharmacy businesses. Is It Worth Investing in CVS Health Based on Wall Street’s Bullish Views?
• Positive Sentiment: CVS Health’s upcoming second-quarter results are being watched for evidence that revenue, earnings, medical costs, and other key operating metrics remain on track. The company previously reported a strong earnings beat and reaffirmed fiscal 2026 EPS guidance of $7.30 to $7.50, providing a positive fundamental backdrop. CVS Health Q2 Earnings: Wall Street’s Insights on Key Metrics
• Positive Sentiment: New availability of pet medications through CVS Pharmacy could modestly expand pharmacy traffic and customer convenience, although the financial impact is likely limited initially. Pet Medications Now Available at CVS Pharmacy

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CVS. DA Davidson upped their target price on shares of CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Deutsche Bank Aktiengesellschaft boosted their price objective on CVS Health from $88.00 to $92.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Bank of America increased their target price on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Royal Bank Of Canada lifted their target price on CVS Health from $107.00 to $113.00 and gave the stock an “outperform” rating in a research report on Thursday, July 9th. Finally, Cantor Fitzgerald upped their price target on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Twenty-one analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, CVS Health presently has a consensus rating of “Moderate Buy” and an average target price of $105.67.

CVS Health Price Performance

Shares of CVS Health stock opened at $104.54 on Friday. CVS Health Corporation has a 52 week low of $61.19 and a 52 week high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a market cap of $133.39 billion, a PE ratio of 46.05, a price-to-earnings-growth ratio of 1.03 and a beta of 0.61. The company’s 50-day moving average price is $101.45 and its two-hundred day moving average price is $87.04.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.36. The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The company’s revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. As a group, sell-side analysts anticipate that CVS Health Corporation will post 7.46 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. CVS Health’s payout ratio is 117.18%.

Insider Activity

In related news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of the company’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the sale, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. This represents a 24.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 3,441,551 shares of company stock worth $323,703,977. Insiders own 0.85% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.